RxDoctor Payments Data

Robert Dean, MD

Urology · Washington, DCNPI 1326119025

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Antares Pharma, Inc. at 25.6% of the total. 2025 is the largest year on record at $366, more than ten times the $36 reported in 2019. That places this record below the midpoint for urology clinicians in DC, where the typical reported total is $1,957.

$1,315in general payments, 2019–2025

Across 44 payments — averaging $29.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$336
  • Boston Scientific$212
  • Endo Pharmaceuticals Inc.$175
  • 180 Medical, Inc.$90
  • Sumitomo Pharma America, Inc.$87
  • Tolmar, Inc.$86
  • plus $329 from 10 others

What the payments were for

  • Food & beverage$1,315100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,315 in reported general payments places this provider in the 40th percentile of 47 urology providers in District of Columbia.

See all urology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$49,169
Medicare patients
171
Services billed
564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Testosterone65$11,743
MyrbetriqMirabegron20$8,945
Tamsulosin Hcl81$1,554
Testosterone Cypionate16$885
Pentoxifylline18$313
Finasteride24$295
Bupropion XlBupropion Hcl25$286
Alfuzosin Hcl ErAlfuzosin Hcl14$134

Paid to pharmacies, not to this prescriber.

Other urology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →